Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human endostatin - Simcere

Next Previous
Drug Profile

Recombinant human endostatin - Simcere

Alternative Names: Endostar; Endu; rh-endostatin; YH-16

Latest Information Update: 21 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Developer Peking University; Simcere Pharmaceutical Group
  • Class Angiostatic proteins; Antineoplastics; Immunotherapies; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Malignant pleural effusion
  • Phase II/III Colorectal cancer
  • Phase II Malignant ascites
  • No development reported Brain metastases; Gastric cancer; Malignant melanoma; Oesophageal cancer; Osteosarcoma; Small cell lung cancer

Most Recent Events

  • 21 Apr 2022 Phase-III clinical trials in Malignant pleural effusion (Combination therapy) in China (Intrapleural), before April 2022 (Simcere pipeline, April 2022) (NCT04914598)
  • 30 Jun 2021 Simcere Pharmaceutical Group plans a phase I trial for Non-small cell lung cancer (Metastatic disease; Late-stage disease, First-line therapy) in the China in July 2021 (IV) (NCT04942301)
  • 11 Jun 2021 Phase-II development is ongoing China for Malignant pleural effusion (Intrapleural)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top